aEgIS Biologics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
aEgIS Biologics - overview
Established
2018
Location
Suwon-si, Gyeonggido, South Korea
Primary Industry
Pharmaceuticals
About
Based in Suwon, South Korea, and founded in 2018, aEgIS Biologics formerly known as Kynogen specializes in the research and development of pharmaceutical treatments and platforms for cancer. In February 2020, aEgIS Biologics raised KRW 4 billion in series A funding led by new investor DAYLI Partners. The company’s core product, KG-IM-001, is designed to overcome resistance and improve efficacy in treating severe immune disorders. This biologic candidate targets key pathways involved in immune regulation, aiming to provide safer and more effective alternatives to conventional treatments.
aEgIS Biologics also engages in R&D for additional therapeutic platforms addressing unmet needs in immunology.
Current Investors
DAYLI Partners, Coolidge Corner Investment
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Specialty Pharmaceuticals
Company Stage
Series A
Total Amount Raised
Subscriber access only
aEgIS Biologics - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - |
| Operating Income (USD) | (1,253,976,000) | (1,745,772,000) | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (1,211,631,000) | (1,728,198,000) | - | - | - |
| % Net Margin | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.